Clinical Report: Enhancing the Immunogenic Response of E. coli FimH
Overview
This study demonstrates that displaying FimH antigens on I53-50 nanoparticles significantly enhances immunogenicity, eliciting robust receptor-blocking antibodies in animal models.
Background
Urinary tract infections (UTIs) are a major public health issue, particularly among women, with uropathogenic E. coli being the primary causative agent. Current vaccine candidates, such as recombinant monomeric FimH, have shown limited immunogenicity, necessitating innovative strategies to enhance their effectiveness. The use of nanoparticle platforms for antigen presentation represents a potential solution to improve vaccine responses.
Data Highlights
Immunogen
Receptor-Blocking Activity
FimH lectin domain on I53-50
Similar to 10-fold higher dose of monomeric FimH-DSG
FimH-DSG on I53-50
Similar to 10-fold higher dose of monomeric FimH-DSG
Key Findings
FimH is a promising vaccine candidate for preventing UTIs caused by uropathogenic E. coli.
Recombinant monomeric FimH requires multiple doses and potent adjuvants to elicit immune responses.
Nanoparticle display of FimH antigens significantly enhances immunogenicity compared to monomeric forms.
Both FimH lectin domain and FimH-DSG on I53-50 nanoparticles elicited similar receptor-blocking activity.
The stabilized FimH-DSG antigen can be produced in high yield and shows improved immunogenicity.
Clinical Implications
The findings support the potential of nanoparticle-based vaccines to improve the immunogenicity of FimH.
Conclusion
The study provides important preclinical data supporting the use of I53-50 nanoparticles for enhancing the immunogenic response of FimH.
by Rebecca S. Cole, Natalie C. Silmon de Monerri, Jacqueline Lypowy, Christopher Ponce, Cara Kobylarz, Lily Liu, Zein Kasbo, Elizabeth Kepl, Tara Ciolino, Art Illenberger, Leslie Gallardo, Annalena Laporte, Danielle Baranova, Rashmi Ravichandran, Laurent O. Chorro, Robert G.K. Donald, Raphael Simon, Neil P. King
